treatment

Iron accelerates MDS progression

Original Publication Date
Article Source
External Web Content
In this issue of Blood, Antypiuk et al, utilizing a murine model, demonstrate that iron overload (IOL), accumulated via a mutation in the iron importer ferroportin, accelerates the myelodysplastic syndrome (MDS) phenotype, leading to exacerbation of marrow failure, inferior…

How I Treat Higher-Risk MDS with Alain Mina, Rami S. Komrokji

Original Publication Date
Article Source
External Web Content
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have…

FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD

Original Publication Date
Article Source
External Web Content
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with graft-versus-host disease (GVHD), according to a news release from the…

ASH 2024 Update: Aplastic Anemia and PNH

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Presenter(s)
Taha Bat, MD
In this webinar, Dr. Taha Bat discusses research most relevant to patients reported over the past year on the biology and treatment on Aplastic Anemia and PNH. These studies were presented at the American Society of Hematology (ASH) 2024 meeting and their findings will be…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.